BioNexus Gene Lab (BGLC) Share-based Compensation (2023 - 2025)

BioNexus Gene Lab (BGLC) reported Share-based Compensation of $794770.0 for Q4 2025, up 983.07% sequentially from -$90001.0 in Q4 2023.

BioNexus Gene Lab (BGLC) Share-based Compensation (2023 - 2025) Analysis & Trends

BioNexus Gene Lab (BGLC) has 2 years of Share-based Compensation data on file, last reported at $794770.0 in Q4 2025.

For the quarter ending Q4 2025, Share-based Compensation changed N/A year-over-year to $794770.0; the trailing twelve-month figure through Dec 2025 stood at $704769.0 (changed N/A YoY), and the FY2025 full-year result was $794770.0, up 463.67% from the prior year.
Share-based Compensation rose to $794770.0 in Q4 2025, from -$90001.0 in the prior quarter.
In the past five years, Share-based Compensation ranged from a high of $794770.0 in Q4 2025 to a low of -$90001.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Share-based Compensation (Qtr)
1	Linde	237.95 Bn	233.99 Bn	4.26 Bn	41.00 Mn
2	Sherwin Williams	78.17 Bn	77.95 Bn	2.78 Bn	29.50 Mn
3	Ecolab	76.02 Bn	75.37 Bn	1.85 Bn	27.10 Mn
4	Air Products & Chemicals	66.38 Bn	65.43 Bn	987.40 Mn	15.90 Mn
5	Ppg Industries	26.02 Bn	24.40 Bn	1.66 Bn	11.00 Mn
6	LyondellBasell Industries	22.51 Bn	19.87 Bn	701.00 Mn	47.00 Mn
7	Chemical & Mining Co Of Chile	19.70 Bn	15.83 Bn	778.60 Mn	-
8	International Flavors & Fragrances	19.51 Bn	18.95 Bn	1.02 Bn	16.00 Mn
9	DuPont de Nemours	18.80 Bn	18.71 Bn	602.00 Mn	16.00 Mn
10	BioNexus Gene Lab	2.82 Mn	-1.14 Mn	-790.00	-

Download Data